

# Pamela S Ohashi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8577277/publications.pdf>

Version: 2024-02-01

266  
papers

38,804  
citations

2975

93  
h-index

2828

191  
g-index

269  
all docs

269  
docs citations

269  
times ranked

41228  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	30.7	53
2	Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. <i>Immunity</i> , 2022, 55, 324-340.e8.	14.3	179
3	Overproduction of IFN $\gamma$ by Cbl-b $\Delta$ Deficient CD8 $^{+}$ T Cells Provides Resistance against Regulatory T Cells and Induces Potent Antitumor Immunity. <i>Cancer Immunology Research</i> , 2022, 10, 437-452.	3.4	6
4	Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. , 2022, 10, e004233.		24
5	DC1s shield Tpex cells to bolster PD-1 blockade. <i>Immunity</i> , 2022, 55, 577-579.	14.3	1
6	Innate Lymphoid Cells: Role in Immune Regulation and Cancer. <i>Cancers</i> , 2022, 14, 2071.	3.7	5
7	The addition of fludarabine to cyclophosphamide for lymphodepleting chemotherapy enhances the persistence of infused NY-ESO-1 TCR anticancer therapy TBI-1301.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2539-2539.	1.6	0
8	Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant Tissue. <i>Prostate Cancer</i> , 2022, 2022, 1-8.	0.6	1
9	External validation of the VICex gene-expression signature (GES) as a novel predictive biomarker for immune checkpoint treatment (ICT).. <i>Journal of Clinical Oncology</i> , 2022, 40, 2510-2510.	1.6	1
10	Translational Control by 4E-BP1/2 Suppressor Proteins Regulates Mitochondrial Biosynthesis and Function during CD8 $^{+}$ T Cell Proliferation. <i>Journal of Immunology</i> , 2022, 208, 2702-2712.	0.8	0
11	Mutations in the RAS/MAPK Pathway Drive Replication Repair $\Delta$ Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. <i>Cancer Discovery</i> , 2021, 11, 1454-1467.	9.4	19
12	Editorial overview: Cancer Immunotherapy: Are we there yet?. <i>Current Opinion in Immunology</i> , 2021, 69, iii-v.	5.5	1
13	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137.	12.8	63
14	Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9044.	4.1	7
15	Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	29
16	Mechanical Stiffness Controls Dendritic Cell Metabolism and Function. <i>Cell Reports</i> , 2021, 34, 108609.	6.4	98
17	Immune Checkpoints and Innate Lymphoid Cells $\Delta$ New Avenues for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5967.	3.7	11
18	Coenzyme A fuels T $\Delta$ cell anti-tumor immunity. <i>Cell Metabolism</i> , 2021, 33, 2415-2427.e6.	16.2	31

#	ARTICLE	IF	CITATIONS
19	Cytotoxic CD4+ T Cells in Bladder Cancer—A New License to Kill. <i>Cancer Cell</i> , 2020, 38, 28-30.	16.8	20
20	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3651.	1.6	130
21	ILC transdifferentiation: roles in cancer progression. <i>Cell Research</i> , 2020, 30, 562-563.	12.0	9
22	Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 544-555.	3.4	48
23	NK Cells Regulate CD8+ T Cell Mediated Autoimmunity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 36.	3.9	20
24	The Roles of CD8+ T Cell Subsets in Antitumor Immunity. <i>Trends in Cell Biology</i> , 2020, 30, 695-704.	7.9	250
25	IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function. <i>Cancer Immunology Research</i> , 2020, 8, 321-333.	3.4	26
26	A Four-Chemokine Signature Is Associated with a T-cell “Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1997-2010.	7.0	91
27	Overproduction of IL-2 by Cbl-b deficient CD4 <sup>+</sup> T cells provides resistance against regulatory T cells. <i>Oncolimmunology</i> , 2020, 9, 1737368.	4.6	10
28	Hypoxia-inducible factor 1 alpha limits dendritic cell stimulation of CD8 T cell immunity. <i>PLoS ONE</i> , 2020, 15, e0244366.	2.5	16
29	ILC regulation of T cell responses in inflammatory diseases and cancer. <i>Seminars in Immunology</i> , 2019, 41, 101284.	5.6	19
30	Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell “Mediated Autoimmunity. <i>Journal of Immunology</i> , 2019, 203, 2791-2806.	0.8	20
31	Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer. <i>Oncolimmunology</i> , 2019, 8, e1665460.	4.6	27
32	Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches. <i>Advances in Cancer Research</i> , 2019, 144, 193-261.	5.0	19
33	Turning the Tide Against Regulatory T Cells. <i>Frontiers in Oncology</i> , 2019, 9, 279.	2.8	47
34	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)., 2019, 7, 72.		38
35	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 773-785.	4.2	94
36	GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. <i>Science Immunology</i> , 2019, 4, .	11.9	85

#	ARTICLE	IF	CITATIONS
37	High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. , 2019, 7, 357.		52
38	Activation of Peroxisome Proliferator-Activated Receptors $\delta$ and $\gamma$ Synergizes with Inflammatory Signals to Enhance Adoptive Cell Therapy. Cancer Research, 2019, 79, 445-451.	0.9	43
39	In vitro $\alpha$ -generated MART $\alpha$ -specific CD 8 T cells display a broader T $\alpha$ -cell repertoire than ex $\alpha$ -vivo na $\alpha$ -ve and tumor $\alpha$ -infiltrating lymphocytes. Immunology and Cell Biology, 2019, 97, 427-434.	2.3	0
40	Rational design and identification of immuno-oncology drug combinations. European Journal of Cancer, 2018, 95, 38-51.	2.8	9
41	Immunoregulatory functions of innate lymphoid cells. , 2018, 6, 121.		9
42	Generation and molecular recognition of melanoma-associated antigen-specific human $\gamma$ $\delta$ T cells. Science Immunology, 2018, 3, .	11.9	43
43	CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling. Blood Advances, 2018, 2, 3506-3514.	5.2	18
44	Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma. Clinical Cancer Research, 2018, 24, 5685-5696.	7.0	76
45	Timed Regulation of 3BP2 Induction Is Critical for Sustaining CD8+ T Cell Expansion and Differentiation. Cell Reports, 2018, 24, 1123-1135.	6.4	9
46	Radiation and Heat Improve the Delivery and Efficacy of Nanotherapeutics by Modulating Intratumoral Fluid Dynamics. ACS Nano, 2018, 12, 7583-7600.	14.6	55
47	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet, The, 2018, 391, 2128-2139.	13.7	1,487
48	K48-linked KLF4 ubiquitination by E3 ligase Mule controls T-cell proliferation and cell cycle progression. Nature Communications, 2017, 8, 14003.	12.8	25
49	A distinct innate lymphoid cell population regulates tumor-associated T cells. Nature Medicine, 2017, 23, 368-375.	30.7	131
50	Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target. Clinical Cancer Research, 2017, 23, 2934-2941.	7.0	44
51	Costimulation, a surprising connection for immunotherapy. Science, 2017, 355, 1373-1374.	12.6	9
52	Notch Shapes the Innate Immunophenotype in Breast Cancer. Cancer Discovery, 2017, 7, 1320-1335.	9.4	98
53	Glycogen Synthase Kinase-3 Modulates Cbl-b and Constrains T Cell Activation. Journal of Immunology, 2017, 199, 4056-4065.	0.8	13
54	Exposure to sequestered self-antigens in vivo is not sufficient for the induction of autoimmune diabetes. PLoS ONE, 2017, 12, e0173176.	2.5	0

#	ARTICLE	IF	CITATIONS
55	RAIDD Mediates TLR3 and IRF7 Driven Type I Interferon Production. Cellular Physiology and Biochemistry, 2016, 39, 1271-1280.	1.6	5
56	Zeroing in on Tumor-Reactive TILs. Cancer Immunology Research, 2016, 4, 719-719.	3.4	2
57	An interaction between Scribble and the NADPH oxidase complex controls M1 macrophage polarization and function. Nature Cell Biology, 2016, 18, 1244-1252.	10.3	41
58	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. , 2016, 4, 37.		1
59	Central tolerance: what you see is what you don't get!. Nature Immunology, 2016, 17, 115-116.	14.5	3
60	B7-H4 is a positive regulator of antitumor immunity. OncoImmunology, 2016, 5, e1050575.	4.6	5
61	Deficiency of the B Cell-Activating Factor Receptor Results in Limited CD169 <sup>+</sup> Macrophage Function during Viral Infection. Journal of Virology, 2015, 89, 4748-4759.	3.4	22
62	Deficiency of MALT1 Paracaspase Activity Results in Unbalanced Regulatory and Effector T and B Cell Responses Leading to Multiorgan Inflammation. Journal of Immunology, 2015, 194, 3723-3734.	0.8	123
63	B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity. Cancer Immunology Research, 2015, 3, 184-195.	3.4	36
64	A Lymphotoxin/Type I IFN Axis Programs CD8+ T Cells To Infiltrate a Self-Tissue and Propagate Immunopathology. Journal of Immunology, 2015, 195, 4650-4659.	0.8	5
65	miR-155 Upregulation in Dendritic Cells Is Sufficient To Break Tolerance In Vivo by Negatively Regulating SHIP1. Journal of Immunology, 2015, 195, 4632-4640.	0.8	53
66	Clinical blockade of PD1 and LAG3 – potential mechanisms of action. Nature Reviews Immunology, 2015, 15, 45-56.	22.7	524
67	Peptide-Pulsed Dendritic Cells Have Superior Ability to Induce Immune-Mediated Tissue Destruction Compared to Peptide with Adjuvant. PLoS ONE, 2014, 9, e92380.	2.5	12
68	Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1060-1065.	7.1	46
69	Mir-155, a central modulator of T cell responses. European Journal of Immunology, 2014, 44, 11-15.	2.9	66
70	Immunological Tolerance – T Cells. , 2014, , 87-102.		1
71	Towards the introduction of the –Immunoscore–™ in the classification of malignant tumours. Journal of Pathology, 2014, 232, 199-209.	4.5	1,151
72	Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity. Immunity, 2014, 40, 949-960.	14.3	191

#	ARTICLE	IF	CITATIONS
73	Chronic viral infection promotes sustained Th1-derived immunoregulatory IL-10 via BLIMP-1. <i>Journal of Clinical Investigation</i> , 2014, 124, 3455-3468.	8.2	79
74	Molecular programming of steady-state dendritic cells: impact on autoimmunity and tumor immune surveillance. <i>Annals of the New York Academy of Sciences</i> , 2013, 1284, 46-51.	3.8	24
75	Shp1 regulates T cell homeostasis by limiting IL-4 signals. <i>Journal of Experimental Medicine</i> , 2013, 210, 1419-1431.	8.5	95
76	ARIH2 is essential for embryogenesis, and its hematopoietic deficiency causes lethal activation of the immune system. <i>Nature Immunology</i> , 2013, 14, 27-33.	14.5	35
77	Reduced type I interferon production by dendritic cells and weakened antiviral immunity in patients with Wiskott-Aldrich syndrome protein deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 815-824.e2.	2.9	27
78	Natural killer cells regulate diverse T cell responses. <i>Trends in Immunology</i> , 2013, 34, 342-349.	6.8	136
79	Cellular and Molecular Requirements for the Selection of In Vitro-Generated CD8 T Cells Reveal a Role for Notch. <i>Journal of Immunology</i> , 2013, 191, 1704-1715.	0.8	17
80	Mobilizing and evaluating anticancer T cells: pitfalls and solutions. <i>Expert Review of Vaccines</i> , 2013, 12, 1325-1340.	4.4	5
81	Involvement of Toso in activation of monocytes, macrophages, and granulocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2593-2598.	7.1	67
82	Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry. <i>Clinical Cancer Research</i> , 2013, 19, 336-346.	7.0	113
83	Micro-RNA 155 Is Required for Optimal CD8+ T Cell Responses to Acute Viral and Intracellular Bacterial Challenges. <i>Journal of Immunology</i> , 2013, 190, 1210-1216.	0.8	112
84	Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. <i>Journal of Clinical Investigation</i> , 2013, 123, 315-328.	8.2	117
85	ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic. <i>Molecular Therapy</i> , 2012, 20, 1148-1157.	8.2	59
86	The 3BP2 Adapter Protein Is Required for Chemoattractant-Mediated Neutrophil Activation. <i>Journal of Immunology</i> , 2012, 189, 2138-2150.	0.8	21
87	The E3 ubiquitin ligase Mule acts through the ATM-p53 axis to maintain B lymphocyte homeostasis. <i>Journal of Experimental Medicine</i> , 2012, 209, 173-186.	8.5	58
88	Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8 <sup>+</sup> T-cell immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 1210-1215.	7.1	298
89	Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. <i>Journal of Experimental Medicine</i> , 2012, 209, 77-91.	8.5	55
90	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	4.4	676

#	ARTICLE	IF	CITATIONS
91	IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature, 2012, 488, 656-659.	27.8	474
92	Dysregulation of immune homeostasis in autoimmune diseases. Nature Medicine, 2012, 18, 42-47.	30.7	94
93	iRhom2 Regulation of TACE Controls TNF-Mediated Protection Against <i>Listeria</i> and Responses to LPS. Science, 2012, 335, 229-232.	12.6	292
94	The NF- $\kappa$ B regulator MALT1 determines the encephalitogenic potential of Th17 cells. Journal of Clinical Investigation, 2012, 122, 4698-4709.	8.2	106
95	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
96	Nuclear factor- $\kappa$ B1 controls the functional maturation of dendritic cells and prevents the activation of autoreactive T cells. Nature Medicine, 2011, 17, 1663-1667.	30.7	75
97	IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology. Cell, 2011, 144, 601-613.	28.9	281
98	Different Toll-Like Receptor Stimuli Have a Profound Impact on Cytokines Required to Break Tolerance and Induce Autoimmunity. PLoS ONE, 2011, 6, e23940.	2.5	18
99	Immunological perspective of self versus tumor antigens: insights from the RIP $\alpha$ model. Immunological Reviews, 2011, 241, 164-179.	6.0	16
100	The Src-Like Adaptor Protein Regulates GM-CSFR Signaling and Monocytic Dendritic Cell Maturation. Journal of Immunology, 2011, 186, 1923-1933.	0.8	37
101	Exposure to IL-15 and IL-21 Enables Autoreactive CD8 T Cells To Respond to Weak Antigens and Cause Disease in a Mouse Model of Autoimmune Diabetes. Journal of Immunology, 2011, 186, 5131-5141.	0.8	41
102	Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice. Hepatology, 2010, 52, 25-32.	7.3	78
103	c-Rel phenocopies PKC $\delta$ , but not Bcl-10 in regulating CD8 <sup>+</sup> T cell activation versus tolerance. European Journal of Immunology, 2010, 40, 867-877.	2.9	9
104	Oxidized ATP inhibits T cell-mediated autoimmunity. European Journal of Immunology, 2010, 40, 2401-2408.	2.9	29
105	c-Rel but not NF- $\kappa$ B1 is important for T regulatory cell development. European Journal of Immunology, 2010, 40, 677-681.	2.9	59
106	Caspase 3 is not essential for the induction of anergy or multiple pathways of CD8 <sup>+</sup> T cell death. European Journal of Immunology, 2010, 40, 3372-3377.	2.9	5
107	Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunology Letters, 2010, 127, 77-84.	2.5	105
108	Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development. Nature Immunology, 2010, 11, 585-593.	14.5	430

#	ARTICLE	IF	CITATIONS
109	Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs). PLoS ONE, 2010, 5, e13940.	2.5	46
110	Regulation of Cytokine-Driven Functional Differentiation of CD8 T Cells by Suppressor of Cytokine Signaling 1 Controls Autoimmunity and Preserves Their Proliferative Capacity toward Foreign Antigens. Journal of Immunology, 2010, 185, 357-366.	0.8	15
111	HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2622-2627.	7.1	39
112	Fighting cancers from within: augmenting tumor immunity with cytokine therapy. Trends in Pharmacological Sciences, 2010, 31, 356-363.	8.7	35
113	Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice. PLoS ONE, 2010, 5, e11003.	2.5	38
114	Differential Role for c-Rel and C/EBP $\beta$ in TLR-Mediated Induction of Proinflammatory Cytokines. Journal of Immunology, 2009, 182, 7212-7221.	0.8	94
115	Transgenic Expression of Hsc70 in Pancreatic Islets Enhances Autoimmune Diabetes in Response to $\beta$ Cell Damage. Journal of Immunology, 2009, 183, 5728-5737.	0.8	21
116	Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. Journal of Experimental Medicine, 2009, 206, 2977-2986.	8.5	282
117	Antigens expressed by myelinating glia cells induce peripheral cross-tolerance of endogenous CD8 <sup>+</sup> T cells. European Journal of Immunology, 2009, 39, 1505-1515.	2.9	9
118	DNA damage- and stress-induced apoptosis occurs independently of PIDD. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 1039-1049.	4.9	45
119	Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nature Medicine, 2009, 15, 528-536.	30.7	198
120	Hematopoietic cell-derived interferon controls viral replication and virus-induced disease. Blood, 2009, 113, 1045-1052.	1.4	48
121	RIP2 contributes to Nod signaling but is not essential for T cell proliferation, T <sub>H</sub> 1 helper differentiation or TLR responses. European Journal of Immunology, 2008, 38, 64-72.	2.9	38
122	IRAK4 kinase activity is required for IRAK4-dependent innate and adaptive immune responses. European Journal of Immunology, 2008, 38, 870-876.	2.9	37
123	Aggravation of viral hepatitis by platelet-derived serotonin. Nature Medicine, 2008, 14, 756-761.	30.7	222
124	LPS/TLR4 signal transduction pathway. Cytokine, 2008, 42, 145-151.	3.2	2,424
125	Targeting of Pancreatic Glia in Type 1 Diabetes. Diabetes, 2008, 57, 918-928.	0.6	32
126	CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2999-3004.	7.1	121



#	ARTICLE	IF	CITATIONS
127	CARD6 Is Interferon Inducible but Not Involved in Nucleotide-Binding Oligomerization Domain Protein Signaling Leading to NF- $\kappa$ B Activation. <i>Molecular and Cellular Biology</i> , 2008, 28, 1541-1552.	2.3	20
128	CD4+ and CD8+ T Cell Survival Is Regulated Differentially by Protein Kinase C $\delta$ , c-Rel, and Protein Kinase B. <i>Journal of Immunology</i> , 2007, 178, 2932-2939.	0.8	49
129	Essential Role for Caspase-8 in Toll-like Receptors and NF- $\kappa$ B Signaling. <i>Journal of Biological Chemistry</i> , 2007, 282, 7416-7423.	3.4	137
130	Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development. <i>European Journal of Immunology</i> , 2007, 37, 2234-2241.	2.9	54
131	The sound of silence: modulating anergy in T lymphocytes. <i>Current Opinion in Immunology</i> , 2007, 19, 658-664.	5.5	32
132	Intricate connections between innate and adaptive autoimmunity. <i>Current Opinion in Immunology</i> , 2007, 19, 603-605.	5.5	7
133	Hsp70 Family Members, Danger Signals and Autoimmunity. , 2007, , 189-211.		4
134	TNF- $\alpha$ is critical for antitumor but not antiviral T cell immunity in mice. <i>Journal of Clinical Investigation</i> , 2007, 117, 3833-45.	8.2	178
135	A Critical Role for the Innate Immune Signaling Molecule IRAK-4 in T Cell Activation. <i>Science</i> , 2006, 311, 1927-1932.	12.6	105
136	Tolerance and Autoimmunity: T Cells. , 2006, , 103-118.		0
137	Suppressing the suppressors. <i>Nature Medicine</i> , 2006, 12, 1000-1002.	30.7	4
138	Generation and Characterization of B7-H4/B7S1/B7x-Deficient Mice. <i>Molecular and Cellular Biology</i> , 2006, 26, 6403-6411.	2.3	72
139	GSK3: an in-Toll-erant protein kinase?. <i>Nature Immunology</i> , 2005, 6, 751-752.	14.5	107
140	Modulating autoimmunity: pick your PI3 kinase. <i>Nature Medicine</i> , 2005, 11, 924-925.	30.7	15
141	Caspase-3-Dependent $\gamma$ -Cell Apoptosis in the Initiation of Autoimmune Diabetes Mellitus. <i>Molecular and Cellular Biology</i> , 2005, 25, 3620-3629.	2.3	129
142	NF- $\kappa$ B Couples Protein Kinase B/Akt Signaling to Distinct Survival Pathways and the Regulation of Lymphocyte Homeostasis In Vivo. <i>Journal of Immunology</i> , 2005, 175, 3790-3799.	0.8	42
143	Differential Control of CD28-Regulated In Vivo Immunity by the E3 Ligase Cbl-b. <i>Journal of Immunology</i> , 2005, 174, 1472-1478.	0.8	41
144	Accessory Protein-Like Is Essential for IL-18-Mediated Signaling. <i>Journal of Immunology</i> , 2005, 174, 5351-5357.	0.8	63

#	ARTICLE	IF	CITATIONS
145	Development of autoreactive diabetogenic T cells in the thymus of NOD mice. <i>Journal of Autoimmunity</i> , 2005, 24, 11-23.	6.5	13
146	Specific Ablation of the Apoptotic Functions of Cytochrome c Reveals a Differential Requirement for Cytochrome c and Apaf-1 in Apoptosis. <i>Cell</i> , 2005, 121, 579-591.	28.9	257
147	PKC $\delta$ Signals Activation versus Tolerance In Vivo. <i>Journal of Experimental Medicine</i> , 2004, 199, 743-752.	8.5	82
148	The Inducible Costimulator Plays the Major Costimulatory Role in Humoral Immune Responses in the Absence of CD28. <i>Journal of Immunology</i> , 2004, 172, 5917-5923.	0.8	56
149	Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. <i>Nature Immunology</i> , 2004, 5, 410-417.	14.5	336
150	TCR affinity and negative regulation limit autoimmunity. <i>Nature Medicine</i> , 2004, 10, 1234-1239.	30.7	138
151	Essential Role of the E3 Ubiquitin Ligase Cbl-b in T Cell Anergy Induction. <i>Immunity</i> , 2004, 21, 167-177.	14.3	308
152	Negative selection and autoimmunity. <i>Current Opinion in Immunology</i> , 2003, 15, 668-676.	5.5	68
153	Weak agonist self-peptides promote selection and tuning of virus-specific T cells. <i>European Journal of Immunology</i> , 2003, 33, 685-696.	2.9	19
154	Autoimmunity. <i>Current Opinion in Immunology</i> , 2003, 15, 647-650.	5.5	11
155	Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell $\alpha$ dependent B cell responses. <i>Nature Immunology</i> , 2003, 4, 765-772.	14.5	185
156	The B7 family member B7-H3 preferentially down-regulates T helper type 1 $\alpha$ mediated immune responses. <i>Nature Immunology</i> , 2003, 4, 899-906.	14.5	479
157	Autoimmune islet destruction in spontaneous type 1 diabetes is not $\beta$ -cell exclusive. <i>Nature Medicine</i> , 2003, 9, 198-205.	30.7	197
158	Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. <i>Nature Medicine</i> , 2003, 9, 1469-1476.	30.7	279
159	IL-1 Receptor-Associated Kinase 4 Is Essential for IL-18-Mediated NK and Th1 Cell Responses. <i>Journal of Immunology</i> , 2003, 170, 4031-4035.	0.8	62
160	Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. <i>Genes and Development</i> , 2003, 17, 883-895.	5.9	412
161	T Cell Antagonism is Functionally Uncoupled from the 21- and 23-kDa Tyrosine-Phosphorylated TCR $\eta$ Subunits. <i>Journal of Immunology</i> , 2003, 171, 845-852.	0.8	15
162	TCR Binding Kinetics Measured with MHC Class I Tetramers Reveal a Positive Selecting Peptide with Relatively High Affinity for TCR. <i>Journal of Immunology</i> , 2003, 171, 2427-2434.	0.8	53

#	ARTICLE	IF	CITATIONS
163	IMMUNOLOGY: Exposing Thy Self. Science, 2002, 298, 1348-1349.	12.6	9
164	The Immune Regulatory Function of Lymphoproliferative Double Negative T Cells In Vitro and In Vivo. Journal of Experimental Medicine, 2002, 196, 261-267.	8.5	113
165	CD28-dependent Activation of Protein Kinase B/Akt Blocks Fas-mediated Apoptosis by Preventing Death-inducing Signaling Complex Assembly. Journal of Experimental Medicine, 2002, 196, 335-348.	8.5	128
166	In Vivo Generation of Cytotoxic T Cells from Epitopes Displayed on Peptide-Based Delivery Vehicles. Journal of Immunology, 2002, 168, 5709-5715.	0.8	8
167	Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance. Journal of Experimental Medicine, 2002, 195, 423-435.	8.5	120
168	Vav1 Controls Integrin Clustering and MHC/Peptide-Specific Cell Adhesion to Antigen-Presenting Cells. Immunity, 2002, 16, 331-343.	14.3	179
169	Enhanced T cell responses contribute to the genetic predisposition of CD8-mediated spontaneous autoimmunity. European Journal of Immunology, 2002, 32, 885.	2.9	5
170	Calcineurin A± plays an exclusive role in TCR signaling in mature but not in immature T cells. European Journal of Immunology, 2002, 32, 1223.	2.9	21
171	Role of ICOS versus CD28 in antiviral immunity. European Journal of Immunology, 2002, 32, 3376-3385.	2.9	82
172	Making and breaking tolerance. Current Opinion in Immunology, 2002, 14, 744-759.	5.5	92
173	Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature, 2002, 416, 750-754.	27.8	766
174	T-cell signalling and autoimmunity: molecular mechanisms of disease. Nature Reviews Immunology, 2002, 2, 427-438.	22.7	133
175	Positive Regulation of T Cell Activation and Integrin Adhesion by the Adapter Fyb/Slap. Science, 2001, 293, 2260-2263.	12.6	278
176	T Cell-Specific Loss of Pten Leads to Defects in Central and Peripheral Tolerance. Immunity, 2001, 14, 523-534.	14.3	524
177	Bcl10 Is a Positive Regulator of Antigen Receptor-Induced Activation of NF- $\kappa$ B and Neural Tube Closure. Cell, 2001, 104, 33-42.	28.9	524
178	Duration and Strength of Extracellular Signal-Regulated Kinase Signals Are Altered During Positive Versus Negative Thymocyte Selection. Journal of Immunology, 2001, 167, 4966-4973.	0.8	114
179	A point mutation in CD28 distinguishes proliferative signals from survival signals. Nature Immunology, 2001, 2, 325-332.	14.5	187
180	ICOS is essential for effective T-helper-cell responses. Nature, 2001, 409, 105-109.	27.8	629

#	ARTICLE	IF	CITATIONS
181	Knockout mice: a paradigm shift in modern immunology. <i>Nature Reviews Immunology</i> , 2001, 1, 11-19.	22.7	53
182	Expression of Active Protein Kinase B in T Cells Perturbs Both T and B Cell Homeostasis and Promotes Inflammation. <i>Journal of Immunology</i> , 2001, 167, 42-48.	0.8	80
183	KNOCKOUT MICE: A PARADIGM SHIFT IN MODERN IMMUNOLOGY. <i>Nature Reviews Immunology</i> , 2001, 1, 11-19.	22.7	57
184	Factors Contributing to Autoimmune Disease. <i>Advances in Experimental Medicine and Biology</i> , 2001, 490, 7-19.	1.6	0
185	Degree of ERK activation influences both positive and negative thymocyte selection. <i>European Journal of Immunology</i> , 2000, 30, 1060-1068.	2.9	58
186	TNF receptor 1 (TNFR1) and CD95 are not required for T cell deletion after virus infection but contribute to peptide-induced deletion under limited conditions. <i>European Journal of Immunology</i> , 2000, 30, 683-688.	2.9	72
187	Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. <i>Nature</i> , 2000, 403, 211-216.	27.8	623
188	Regulation of T cell activation, anxiety, and male aggression by RGS2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 12272-12277.	7.1	264
189	Negative Regulation of T Cell Proliferation and Interleukin 2 Production by the Serine Threonine Kinase Gsk-3. <i>Journal of Experimental Medicine</i> , 2000, 192, 99-104.	8.5	142
190	Protein Kinase B Regulates T Lymphocyte Survival, Nuclear Factor $\kappa$ B Activation, and Bcl-XL Levels in Vivo. <i>Journal of Experimental Medicine</i> , 2000, 191, 1721-1734.	8.5	309
191	Role of Antigen-Presenting Cells in Mediating Tolerance and Autoimmunity. <i>Journal of Experimental Medicine</i> , 2000, 191, 2021-2028.	8.5	148
192	The Quantity of TCR Signal Determines Positive Selection and Lineage Commitment of T Cells. <i>Journal of Immunology</i> , 2000, 165, 6252-6261.	0.8	29
193	Cbl-b Is a Negative Regulator of Receptor Clustering and Raft Aggregation in T Cells. <i>Immunity</i> , 2000, 13, 463-473.	14.3	205
194	Function of PI3K $\delta$ in Thymocyte Development, T Cell Activation, and Neutrophil Migration. <i>Science</i> , 2000, 287, 1040-1046.	12.6	1,003
195	Differential Roles of Interleukin 15 mRNA Isoforms Generated by Alternative Splicing in Immune Responses in Vivo. <i>Journal of Experimental Medicine</i> , 2000, 191, 157-170.	8.5	131
196	Immobilization of glycosylphosphatidylinositol-anchored proteins inhibits T cell growth but not function. <i>International Immunology</i> , 1999, 11, 1381-1393.	4.0	27
197	The role of T-cell receptor dimerization in T-cell activation. <i>Trends in Immunology</i> , 1999, 20, 568-576.	7.5	47
198	Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. <i>Nature</i> , 1999, 402, 43-47.	27.8	119

#	ARTICLE	IF	CITATIONS
199	Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. <i>Nature</i> , 1999, 402, 304-309.	27.8	1,809
200	The oncogene product Vav is a crucial regulator of primary cytotoxic T cell responses but has no apparent role in CD28-mediated co-stimulation. <i>European Journal of Immunology</i> , 1999, 29, 1709-1718.	2.9	35
201	Absence of co-stimulation and not the intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo. <i>European Journal of Immunology</i> , 1999, 29, 2156-2166.	2.9	17
202	Identification of a cross-reactive self ligand in virus-mediated autoimmunity. <i>European Journal of Immunology</i> , 1999, 29, 2886-2896.	2.9	37
203	SELECTION OF THE T CELL REPERTOIRE. <i>Annual Review of Immunology</i> , 1999, 17, 829-874.	21.8	451
204	TRAF2 Deficiency Results in Hyperactivity of Certain TNFR1 Signals and Impairment of CD40-Mediated Responses. <i>Immunity</i> , 1999, 11, 379-389.	14.3	128
205	Signals involved in thymocyte positive and negative selection. <i>Seminars in Immunology</i> , 1999, 11, 263-272.	5.6	32
206	Formation of TCR dimers/trimers as a crucial step for T cell activation. <i>European Journal of Immunology</i> , 1998, 28, 2571-2579.	2.9	44
207	Inhibition of TCR triggering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism. <i>European Journal of Immunology</i> , 1998, 28, 3110-3119.	2.9	47
208	Requirement of the IL-2 Receptor $\beta$ Chain for the Development of V $\beta$ 3 Dendritic Epidermal T Cells. <i>Journal of Investigative Dermatology</i> , 1998, 110, 961-965.	0.7	41
209	The Transcription Factor NF-ATc1 Regulates Lymphocyte Proliferation and Th2 Cytokine Production. <i>Immunity</i> , 1998, 8, 115-124.	14.3	314
210	The Inositol Polyphosphate 5-Phosphatase Ship Is a Crucial Negative Regulator of B Cell Antigen Receptor Signaling. <i>Journal of Experimental Medicine</i> , 1998, 188, 1333-1342.	8.5	204
211	The Transcription Factor Interferon Regulatory Factor 1 (IRF-1) Is Important during the Maturation of Natural Killer 1.1+ T Cell Receptor $\alpha\beta$ (NK1+ T) Cells, Natural Killer Cells, and Intestinal Intraepithelial T Cells. <i>Journal of Experimental Medicine</i> , 1998, 187, 967-972.	8.5	171
212	Vav Regulates Peptide-specific Apoptosis in Thymocytes. <i>Journal of Experimental Medicine</i> , 1998, 188, 2099-2111.	8.5	91
213	ALLOREACTIVE CYTOTOXIC T CELLS RECOGNIZE MINOR TRANSPLANTATION ANTIGENS PRESENTED BY MAJOR HISTOCOMPATIBILITY COMPLEX CLASS Ib MOLECULES1. <i>Transplantation</i> , 1998, 66, 646-650.	1.0	6
214	T Cell Tolerance versus Tumor Immunity or Autoimmunity. , 1998, , 199-212.		0
215	Impaired CD28-mediated Interleukin 2 Production and Proliferation in Stress Kinase SAPK/ERK1 Kinase (SEK1)/Mitogen-activated Protein Kinase Kinase 4 (MKK4)-deficient T Lymphocytes. <i>Journal of Experimental Medicine</i> , 1997, 186, 941-953.	8.5	126
216	A Regulatory Role for TRAF1 in Antigen-induced Apoptosis of $\alpha\beta$ T Cells. <i>Journal of Experimental Medicine</i> , 1997, 185, 1777-1783.	8.5	126

#	ARTICLE	IF	CITATIONS
217	Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy. <i>Journal of Experimental Medicine</i> , 1997, 186, 645-653.	8.5	286
218	Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function. <i>Science</i> , 1997, 275, 540-543.	12.6	543
219	Peptide-Induced Positive Selection of TCR Transgenic Thymocytes in a Coreceptor-Independent Manner. <i>Immunity</i> , 1997, 6, 643-653.	14.3	41
220	Distinct Roles for LFA-1 and CD28 during Activation of Naive T Cells: Adhesion versus Costimulation. <i>Immunity</i> , 1997, 7, 549-557.	14.3	402
221	Early Lethality, Functional NF- $\kappa$ B Activation, and Increased Sensitivity to TNF-Induced Cell Death in TRAF2-Deficient Mice. <i>Immunity</i> , 1997, 7, 715-725.	14.3	778
222	CD44 Regulates Hematopoietic Progenitor Distribution, Granuloma Formation, and Tumorigenicity. <i>Blood</i> , 1997, 90, 2217-2233.	1.4	347
223	T-Cell-Independent Antiviral B Cell Responses in CD45-Deficient Mice. <i>Cellular Immunology</i> , 1997, 175, 12-15.	3.0	5
224	Autoimmunity A bias from tolerance to immunity. <i>Current Opinion in Immunology</i> , 1997, 9, 815-817.	5.5	3
225	Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor-transgenic CTLA-4-deficient mice. <i>European Journal of Immunology</i> , 1997, 27, 1887-1892.	2.9	73
226	Peptide-induced T cell receptor down-regulation on naive T cells predicts agonist/partial agonist properties and strictly correlates with T cell activation. <i>European Journal of Immunology</i> , 1997, 27, 2195-2203.	2.9	83
227	Four types of Ca <sup>2+</sup> signals in naive CD8 <sup>+</sup> cytotoxic T cells after stimulation with T cell agonists, partial agonists and antagonists. <i>European Journal of Immunology</i> , 1997, 27, 3414-3419.	2.9	23
228	ACUTE GRAFT-VERSUS-HOST DISEASE WITHOUT COSTIMULATION VIA CD281. <i>Transplantation</i> , 1997, 63, 1042-1044.	1.0	31
229	CD44 Regulates Hematopoietic Progenitor Distribution, Granuloma Formation, and Tumorigenicity. <i>Blood</i> , 1997, 90, 2217-2233.	1.4	15
230	Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30 $\alpha$ -Deficient Mice. <i>Cell</i> , 1996, 84, 551-562.	28.9	316
231	Duration of TCR Stimulation Determines Costimulatory Requirement of T Cells. <i>Immunity</i> , 1996, 5, 41-52.	14.3	347
232	On the role of antigen in maintaining cytotoxic T-cell memory.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 9716-9723.	7.1	223
233	Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock. <i>European Journal of Immunology</i> , 1996, 26, 1074-1082.	2.9	58
234	T cell responses are governed by avidity and co-stimulatory thresholds. <i>European Journal of Immunology</i> , 1996, 26, 2017-2022.	2.9	101

#	ARTICLE	IF	CITATIONS
235	Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo. European Journal of Immunology, 1996, 26, 3055-3060.	2.9	119
236	T cell selection and autoimmunity: flexibility and tuning. Current Opinion in Immunology, 1996, 8, 808-814.	5.5	48
237	Development of insulinitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity.. Journal of Experimental Medicine, 1996, 183, 2143-2152.	8.5	118
238	LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor.. Journal of Experimental Medicine, 1996, 183, 1415-1426.	8.5	256
239	Mature T cell reactivity altered by peptide agonist that induces positive selection.. Journal of Experimental Medicine, 1996, 183, 1093-1104.	8.5	145
240	SKIN ALLOGRAFT REJECTION IN CD28-DEFICIENT MICE1. Transplantation, 1996, 61, 352-355.	1.0	83
241	T-Cell Development and Tolerance in Virus-Specific Transgenic Models. , 1996, , 29-43.		0
242	T lymphocyte development in p56lck deficient mice: allelic exclusion of the TcR $\beta^2$ locus is incomplete but thymocyte development is not restored by TcR $\beta^2$ or TcR $\beta^1\beta^2$ transgenes. European Journal of Immunology, 1995, 25, 1312-1318.	2.9	51
243	Immunological function of a defined T-cell population tolerized to low-affinity self antigens. Nature, 1995, 374, 68-69.	27.8	89
244	Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 444-448.	7.1	127
245	Evidence for a selective and multi-step model of T cell differentiation: CD4+CD8low thymocytes selected by a transgenic T cell receptor on major histocompatibility complex class I molecules. European Journal of Immunology, 1994, 24, 1982-1987.	2.9	23
246	Class II major histocompatibility complex-restricted T cell function in CD4-deficient mice. European Journal of Immunology, 1994, 24, 2213-2218.	2.9	104
247	Escape of Thymocytes and Mature T Cells from Clonal Deletion Due to Limiting Tolerogen Expression Levels. Cellular Immunology, 1994, 158, 342-352.	3.0	54
248	Thymocyte Selection and Peripheral Tolerance Using the Lymphocytic Choriomeningitis Virus as a Model Antigen. , 1994, , 113-133.		2
249	The lack of CD8 $\beta$ cytoplasmic domain resulted in a dramatic decrease in efficiency in thymic maturation but only a moderate reduction in cytotoxic function of CD8+ T lymphocytes. European Journal of Immunology, 1993, 23, 2834-2840.	2.9	47
250	Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell, 1993, 73, 457-467.	28.9	1,640
251	Normal B lymphocyte development but impaired T cell maturation in CD45-Exon6 protein tyrosine phosphatase-deficient mice. Cell, 1993, 74, 143-156.	28.9	500
252	Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell, 1993, 75, 83-97.	28.9	590



#	ARTICLE	IF	CITATIONS
253	Enhanced positive selection of a transgenic TCR by a restriction element that does not permit negative selection. <i>International Immunology</i> , 1993, 5, 131-138.	4.0	37
254	Expression of a tumor necrosis factor alpha transgene in murine pancreatic beta cells results in severe and permanent insulinitis without evolution towards diabetes.. <i>Journal of Experimental Medicine</i> , 1992, 176, 1719-1731.	8.5	159
255	T cells causing immunological disease. <i>Seminars in Immunopathology</i> , 1992, 14, 105-13.	4.0	2
256	Vaccination or tolerance to prevent diabetes. <i>European Journal of Immunology</i> , 1992, 22, 3149-3153.	2.9	18
257	Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. <i>Cell</i> , 1991, 65, 305-317.	28.9	1,181
258	Transgenic Mice as an in vivo Model for Self-Reactivity. <i>Immunological Reviews</i> , 1990, 118, 257-283.	6.0	14
259	Distinct sequence of negative or positive selection implied by thymocyte T-cell receptor densities. <i>Nature</i> , 1990, 346, 861-863.	27.8	130
260	Specific deletion of the J- $\alpha$ locus in murine $\beta$ / $\alpha$ T cell clones and studies using transgenic mice. <i>European Journal of Immunology</i> , 1990, 20, 517-522.	2.9	12
261	Expression of CD4 can confer major histocompatibility complex class II-associated superantigen reactivity upon a T cell receptor derived from a CD8-dependent cytotoxic T lymphocyte clone. <i>European Journal of Immunology</i> , 1990, 20, 2471-2477.	2.9	2
262	Thymic ontogeny and selection of $\beta$ and $\gamma$ T cells. <i>Trends in Immunology</i> , 1989, 10, 403-407.	7.5	53
263	Molecular analysis of the antigen receptor of virus-specific cytotoxic T cells and identification of a new $V\beta$ family. <i>European Journal of Immunology</i> , 1987, 17, 1843-1846.	2.9	90
264	T cell-specific gamma genes in C57BL/10 mice. Sequence and expression of new constant and variable region genes.. <i>Journal of Experimental Medicine</i> , 1986, 163, 1203-1212.	8.5	160
265	Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer. <i>Nature</i> , 1985, 316, 606-609.	27.8	300
266	Reorganization of unique and repetitive sequences during nuclear development in <i>Tetrahymena thermophila</i> . <i>Canadian Journal of Biochemistry</i> , 1982, 60, 847-853.	1.4	51